Characterization of anticoagulant heparinoids by immunoprofiling. - Wikidata - wikimedia - TriplyDB

Characterization of anticoagulant heparinoids by immunoprofiling.

Characterization of anticoagulant heparinoids by immunoprofiling.

http://www.wikidata.org/entity/Q33376879

about

Sulf1 and Sulf2 Differentially Modulate Heparan Sulfate Proteoglycan Sulfation during Postnatal Cerebellum Development: Evidence for Neuroprotective and Neurite Outgrowth Promoting Functions Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer ScFv anti-heparan sulfate antibodies unexpectedly activate endothelial and cancer cells through p38 MAPK: implications for antibody-based targeting of heparan sulfate proteoglycans in cancer.Immobilization of heparan sulfate on electrospun meshes to support embryonic stem cell culture and differentiation.Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera.SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.Age-related changes in rat myocardium involve altered capacities of glycosaminoglycans to potentiate growth factor functions and heparan sulfate-altered sulfation Characterization of the interaction between the chlamydial adhesin OmcB and the human host cell.Proteoglycomics: recent progress and future challenges.'Immunosequencing' of heparan sulfate from human cell lines and rat kidney: the (GlcNS6S-IdoA2S)₃ motif, recognized by antibody NS4F5, is located towards the non-reducing end.Conservation of anatomically restricted glycosaminoglycan structures in divergent nematode species.Rapid point-of-care assay of enoxaparin anticoagulant efficacy in whole blood.

P2860

Q28550135-F5BC68F3-5538-4775-AE9E-D0042B34CA42 Q33803148-6A3BADD6-9F61-48C1-999A-B85DD09959E5 Q34477717-BF2329E0-FC00-4D54-B7E4-445CB0D14487 Q34509764-4D8BFE72-BB5F-48B2-89A6-EF5B1B0AB103 Q34757062-8DEF5D57-8854-4F65-B408-DA827053CBE7 Q35180876-8BB6890D-85D4-4A61-88E4-7AB64A2EBF24 Q35221119-FD02ACC2-4549-46D4-8976-75A24DB85C38 Q35656129-8045A8DD-3CFE-4E58-80B0-88516C6E7E9F Q35879491-93453E4A-3B09-4291-9E33-4C155EF0DB89 Q37335962-20E98097-486B-4F75-960A-B4BE3DE88EB6 Q37745062-B03C2EA9-4E44-49A1-87BE-9A050B775154 Q38995855-CA25FD29-1C97-4F39-8493-B875C814336A Q41058884-B8E3A841-1104-407E-8599-8FDAB6BCD644 Q41460353-5B7F60B8-756E-4E65-9AA8-D66C144F950F

P2860

Characterization of anticoagulant heparinoids by immunoprofiling.

http://www.wikidata.org/entity/Q33376879

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Characterization of anticoagulant heparinoids by immunoprofiling.

@ast

Characterization of anticoagulant heparinoids by immunoprofiling.

@en

type

label

Characterization of anticoagulant heparinoids by immunoprofiling.

@ast

Characterization of anticoagulant heparinoids by immunoprofiling.

@en

prefLabel

Characterization of anticoagulant heparinoids by immunoprofiling.

@ast

Characterization of anticoagulant heparinoids by immunoprofiling.

@en

P1433

Q33376879-5C7E91C5-9118-464C-AF9A-C3299ABA91DE

P1476

Q33376879-23007FAC-B8A3-4F8B-9627-3605959B797E

P2093

Q33376879-0AACB7A8-14CC-4E9C-B99C-7B42A898C6AD

Q33376879-420473E8-6BAA-4FEC-BD3B-8A67661117FD

Q33376879-4AA6BEAE-3F1D-432F-820B-2FB3B81CF393

Q33376879-59E3CF0E-8F16-48D0-BA12-758A26E16848

Q33376879-7EE62CCB-F875-4E4D-A342-2996BC846A3D

Q33376879-9E4E2CE9-6C6D-46F0-8FC5-CA76C8CE744A

Q33376879-CFEDD5B9-CBBE-47B0-8986-B1ECF89B9631

Q33376879-F61D62C9-0C6B-46F0-B735-7348C6619166

P2860

Q33376879-03A6E109-45F2-4252-B156-EA0E7147B695

Q33376879-052AADB2-4E26-41A6-8E4A-51E15EA38C17

Q33376879-0D95985B-123F-42AF-89F6-E0A0A98A3381

Q33376879-0EAC9004-28C3-47C7-ADF7-EEC271C18339

Q33376879-1168AA39-A747-448F-B460-582CA418104D

Q33376879-125DC800-8DEB-46F6-857E-77CC65F355CF

Q33376879-16803DDA-5189-42BA-8AB0-EE5B631F49FB

Q33376879-2CAB4B0E-2F5E-4C95-87FB-BC7DA8AAF719

Q33376879-3D6EA029-B089-4EAF-904C-E97E4E4429C7

Q33376879-3DB0238D-9446-49AE-94F5-048F2E308F32

P2888

Q33376879-97A241E2-9F66-49DE-B4F9-816299B6B184

P304

Q33376879-A633D62A-51C8-4E5B-93AC-68AAAC48F218

P31

Q33376879-52A42C4F-334F-4409-A2B8-7791FFFF0A5E

P356

Q33376879-D3BBE9AB-41FF-452F-A6BB-3297A4DF24BE

P433

Q33376879-37FD41F4-EE90-4D56-8CCE-72A9F17C828A

P478

Q33376879-EAA0B49F-4DFE-494C-8020-609FD134ACCA

P50

Q33376879-587D441E-D20E-455E-B32E-3207C1B9378F

P577

Q33376879-9BC951B7-47CC-4791-9AF5-4C489FF8C417

P5875

Q33376879-D32EF310-CA4A-4022-B285-519B35F607E2

P6179

Q33376879-C9637CDA-7CF8-479C-907F-9C78CA22D475

P698

Q33376879-CD6AD13A-D68E-4D0F-8BF1-3D5F88BE90A9

P921

Q33376879-42EC549B-4690-4000-A9D0-2B0343A3EC8A

P932

Q33376879-C3CE6408-1573-4CDC-9DC0-BF05C4F77738

P356

S10719-007-9070-Z

P1433

Glycoconjugate Journal

P1476

Characterization of anticoagulant heparinoids by immunoprofiling.

@en

P2093

Angelique L Rops

http://www.w3.org/2001/XMLSchema#string

Els M van de Westerlo

http://www.w3.org/2001/XMLSchema#string

Jo H Berden

http://www.w3.org/2001/XMLSchema#string

Joost F Lensen

http://www.w3.org/2001/XMLSchema#string

Lambert P van den Heuvel

http://www.w3.org/2001/XMLSchema#string

Nicole C Smits

http://www.w3.org/2001/XMLSchema#string

Tessa J Wijnhoven

http://www.w3.org/2001/XMLSchema#string

Toin H van Kuppevelt

http://www.w3.org/2001/XMLSchema#string

P2860

Human single chain antibodies against heparin: selection, characterization, and effect on coagulation.

Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies.

Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney.

3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3.

Characterization of anti-heparan sulfate phage display antibodies AO4B08 and HS4E4.

Orgaran in heparin-induced thrombocytopenia.

A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?

Production and chemical processing of low molecular weight heparins.

Structural characterization of low molecular weight heparins.

Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine.

P2888

s10719-007-9070-z

P304

177-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10719-007-9070-Z

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Johan Van Der Vlag

P577

2007-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5935046

http://www.w3.org/2001/XMLSchema#string

P6179

1035428870

http://www.w3.org/2001/XMLSchema#string

P698

17909966

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

2234449

http://www.w3.org/2001/XMLSchema#string